UK-based molecular diagnostics developer Lumora has partnered with the Foundation for Innovative New Diagnostics to develop a rapid, high-throughput malaria diagnostic assay to screen patients in the developing world.
The device, which the scientists are developing under a two-year, €1.3 million grant from Germany's Federal Ministry of Education and Research, uses cytometric bead arrays to quantitate protein biomarkers in patients' exhaled breath condensate.
Magna is spearheading a public-private consortium to develop a point-of-care molecular testing platform based on magnetic nanoparticles and PCR amplification. Other partners in the consortium include the Fraunhofer Institute and Siemens.
The company will use part of the €1 million award to investigate biomarkers that will aid in determining which patients are the best candidates for treatment with its MOR202 antibody program, a company official said.